Literature DB >> 16569375

Nephrogenic systemic fibrosis: an update.

Shawn E Cowper1, Philip J Boyer.   

Abstract

Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is an emerging systemic fibrosing disorder that develops in the setting of renal insufficiency. Since its recognition in 1997, several case reports of NSF have been published in the rheumatology literature, reflecting the increasing incidence and recognition of this disorder in the United States and abroad. As rheumatology professionals are commonly the first to encounter newly developing cases, it is imperative that they recognize the symptoms and comorbidities of NSF and initiate work-up and treatment. To date, the precise causes of NSF have not been established; however, several promising lines of inquiry have led to a new model of the disorder. This model speculates that circulating fibrocytes of bone marrow origin are aberrantly recruited to the skin and other systemic sites by a process likely triggered or exacerbated by endothelial damage.

Entities:  

Mesh:

Year:  2006        PMID: 16569375     DOI: 10.1007/s11926-006-0056-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  23 in total

1.  Scleromyxoedema-like changes in four renal dialysis patients.

Authors:  V Hubbard; A Davenport; M Jarmulowicz; M Rustin
Journal:  Br J Dermatol       Date:  2003-03       Impact factor: 9.302

Review 2.  Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure.

Authors:  Pieter Evenepoel; Miranda Zeegers; Siegfried Segaert; Kathleen Claes; Dirk Kuypers; Bart Maes; Patrick Flamen; Sabine Fransis; Yves Vanrenterghem
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

3.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight.

Authors:  Shawn E Cowper; Richard Bucala; Philip E Leboit
Journal:  Semin Arthritis Rheum       Date:  2006-02       Impact factor: 5.532

Review 4.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review.

Authors:  Sumanth R Daram; Cherise M Cortese; Bahar Bastani
Journal:  Am J Kidney Dis       Date:  2005-10       Impact factor: 8.860

5.  Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis.

Authors:  M Gilliet; A Cozzio; G Burg; F O Nestle
Journal:  Br J Dermatol       Date:  2005-03       Impact factor: 9.302

6.  A case of nephrogenic fibrosing dermopathy.

Authors:  A W Tan; S H Tan; T Y Lian; S K Ng
Journal:  Ann Acad Med Singapore       Date:  2004-07       Impact factor: 2.473

7.  Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis.

Authors:  Pedro W Baron; Kenneth Cantos; Donald J Hillebrand; Ke-Qin Hu; Okechukwu N Ojogho; Sandra Nehlsen-Cannarella; Waldo Concepcion
Journal:  Am J Dermatopathol       Date:  2003-06       Impact factor: 1.533

Review 8.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood.

Authors:  Timothy E Quan; Shawn Cowper; Sou-Pan Wu; Linda K Bockenstedt; Richard Bucala
Journal:  Int J Biochem Cell Biol       Date:  2004-04       Impact factor: 5.085

9.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

Authors:  Julian M Mackay-Wiggan; David J Cohen; Mark A Hardy; Elizabeth H Knobler; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

10.  Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases.

Authors:  Brian N Streams; Vincent Liu; Nanette Liégeois; Samuel M Moschella
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

View more
  12 in total

1.  Magnetic resonance angiography (MRA) of the calf station at 3.0 T: intraindividual comparison of non-enhanced ECG-gated flow-dependent MRA, continuous table movement MRA and time-resolved MRA.

Authors:  Stefan Haneder; Ulrike I Attenberger; Philipp Riffel; Thomas Henzler; Stefan O Schoenberg; Henrik J Michaely
Journal:  Eur Radiol       Date:  2011-01-28       Impact factor: 5.315

Review 2.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

Review 3.  [Nephrogenic systemic fibrosis].

Authors:  Stefan Becker; Oliver Witzke; Andreas Kribben
Journal:  Med Klin (Munich)       Date:  2009-04-01

Review 4.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

5.  Assisting vascular access surgery planning for hemodialysis by using MR, image segmentation techniques, and computer simulations.

Authors:  M A G Merkx; A S Bode; W Huberts; J Oliván Bescós; J H M Tordoir; M Breeuwer; F N van de Vosse; E M H Bosboom
Journal:  Med Biol Eng Comput       Date:  2013-03-23       Impact factor: 2.602

6.  Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Authors:  B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West
Journal:  Br J Radiol       Date:  2014-10       Impact factor: 3.039

Review 7.  Nephrogenic systemic fibrosis.

Authors:  Diego R Martin
Journal:  Pediatr Radiol       Date:  2007-12-11

Review 8.  Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors:  Hale Ersoy; Frank J Rybicki
Journal:  J Magn Reson Imaging       Date:  2007-11       Impact factor: 4.813

9.  Human brain tumor imaging with a protein-binding MR contrast agent: initial experience.

Authors:  Marco Essig; Martin Rohrer; Frederik Giesel; Jochen Tüttenberg; Marc-André Weber; Hendrik Michaely; Lars Gerigk; Matthias Voth
Journal:  Eur Radiol       Date:  2009-08-12       Impact factor: 5.315

10.  Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure.

Authors:  Scott O Grebe; Marc Borrmann; Alexander Altenburg; Ulrich Wesselman; Dietmar Hein; Patrick Haage
Journal:  Clin Exp Nephrol       Date:  2008-06-14       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.